Zydus Cadila Strengthens Pipeline With 35 FDA Approvals

As Company Sees Double-Digit Domestic Growth

 
• By Akriti Seth

India’s Zydus Cadila is working on strengthening its pipeline with 35 product approvals from the FDA over the course of its most recent financial year. The company also filed for 22 new ANDAs during FY2021. And ahead of recently launching the world’s first biosimilar to Roche’s Kadcyla (trastuzumab emtansine) in India, the company reported significant growth in its domestic business. 

FDA approvals
Zydus Cadila receives 35 FDA approvals and files for 22 new ANDAs • Source: Alamy

Zydus Cadila says it is “strengthening its regulatory pipeline” after receiving 35 abbreviated new drug application approvals from the US Food and Drug Administration during its financial year ended 31 March 2021. The company filed 22 additional ANDAs during the year as the company’s growing US formulations business registered revenues of INR15.09bn ($206.7m) in the fourth quarter alone.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin